Organic Compounds
US-2016338978-A1 · Nov 24, 2016 · US
US9468606B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9468606-B2 |
| Application number | US-201414230535-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 31, 2014 |
| Priority date | Mar 31, 2014 |
| Publication date | Oct 18, 2016 |
| Grant date | Oct 18, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A powder is disclosed including core/shell particles having an average particle size of less than 1000 microns, each particle contains a liquid core that is substantially free of water and includes A) a polar liquid having a percent surface polarity of at least 24%, an active ingredient, and C) from about 0.1% to about 20% by weight of at least one solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. The powder can be used to topically administer the active ingredient to a human or animal.
Opening claim text (preview).
We claim: 1. A powder comprising core/shell particles having an average particle size of less than 1000 microns, each particle comprising: a liquid core that is substantially free of water and comprises A) a polar liquid having a percent surface polarity of at least 24%, B) an acid active agent comprising from about 0.001% to about 20% ibuprofen by weight of the powder, and C) from about 0.1% to about 20% by weight of at least one basic solubility enhancing agent that is not an active ingredient; and a shell comprising hydrophobic particles. 2. The powder of claim 1 , wherein the hydrophobic particles comprise hydrophobic fumed silica. 3. The powder of claim 2 , wherein the polar liquid comprises a polyol selected from the group consisting of glycerols, polyglycerols, glycols, polyglycols, and mixtures thereof. 4. The powder of claim 3 , wherein the polyol is selected from the group consisting of glycerol, diglycerol, triglycerol, tetraglycerol, polyglycerols having more than 4 glycerol groups, and mixtures thereof. 5. The powder of claim 3 , wherein the polar liquid comprises at least about 50 percent by weight of a glycerol, polyglycerol, or mixture thereof. 6. The powder of claim 1 , wherein the acidic active agent comprises from about 0.01% to about 10% by weight of the powder. 7. The powder of claim 6 , wherein the acidic active agent comprises from about 0.1% to about 5% by weight of the powder. 8. The powder of claim 1 , wherein the basic solubility enhancer is selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, ethylamine, diethylamine, triethylamine, diisopropylethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, triisopropanolamine and mixtures thereof. 9. The powder of claim 1 , wherein the basic solubility enhancer is in an amount from about 1% to about 5% by weight of the powder. 10. A method for enhancing the topical application of a benefit agent which comprises topically administering to the skin of a human or animal the powder composition according to claim 1 . 11. The method of claim 10 , wherein the active agent comprises from about 0.01% to about 10% by weight of the powder. 12. The method of claim 11 , wherein the active agent comprises from about 0.1% to about 5% by weight of the powder. 13. The method of claim 10 , wherein the basic solubility enhancer is selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, magnesium hydroxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, ethylamine, diethylamine, triethylamine, diisopropylethylamine, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, triisopropanolamine and mixtures thereof. 14. The method of claim 13 , wherein the basic solubility enhancer is in an amount from about 1% to about 5% by weight of the powder.
for baldness or alopecia · CPC title
Inorganic compounds · CPC title
Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title
The particulate/core comprising organic material · CPC title
Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.